Categories for... News

News

First patients dosed in Phase 1a clinical trial of UCL-backed G-Quadruplex (G4) targeting treatment for solid tumors, including pancreatic cancer

READ ARTICLE

News

Sygnature Discovery Appoints Industry Leaders To Board Of Directors

READ ARTICLE

News

Sygnature Discovery invests £3.75M in Compound Management to provide cutting-edge hit finding capabilities to pharma and biotechnology customers

READ ARTICLE

News

Sygnature Discovery collaborates with Axol Bioscience to utilize ​human ​iPSC-derived microglial cells in high-content imaging drug discovery screening workflows.

READ ARTICLE

News Targeted Protein Degradation

Sygnature Discovery and UBE Corporation successfully identify potent SHP2 degrader compounds

READ ARTICLE

News

Sygnature Discovery’s hit finding expertise in high demand as cardiac biotech customer, River BioMedics, receives an additional €2M seed investment

READ ARTICLE

News

Sygnature Discovery accelerates global growth with major North American acquisition

READ ARTICLE

News

Sygnature Discovery launches its in vivo LPS model to ​p​​rofile early-stage anti-inflammatory drugs​

READ ARTICLE

News

Sygnature Discovery and Daewoong Pharma announce research collaboration

READ ARTICLE

News

New platform set to accelerate early-stage targeted protein degradation

READ ARTICLE

News

Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its market-leading capabilities

READ ARTICLE

News

Sygnature Discovery partners the Oncology Development Programme (ODP2) to find UK-based breakthroughs in Oncology

READ ARTICLE